

May 26, 2006
AnGes MG, Inc.

**Results of Phase I Clinical Trials of NFκB Decoy Oligo
in the Treatment of Atopic Dermatitis**

Phase I clinical trials of NFκB decoy oligo in the treatment of atopic dermatitis have been under way since September 2005. AnGes MG, Inc. is pleased to announce that the results confirmed the safety of this drug.

NFκB decoy oligo is being developed as a nucleic acid drug indicated for immuno-inflammatory diseases such as atopic dermatitis and rheumatoid arthritis. Of these, atopic dermatitis is a disease for which the development of a new treatment drug is eagerly awaited, since, although there are believed to be as many as 1.4 million patients in Japan, effective treatment methods, especially for severe atopic dermatitis on the face, have yet to be developed.

NFκB decoy oligo, because of its characteristic of specifically suppressing transcription factors, has the potential to become an epoch-making atopic dermatitis drug that is effective and induces few adverse reactions and therefore AnGes MG has been stepping up development of this drug.

The phase I clinical trials were carried out with the aim of confirming the drug's safety for transdermal administration. As a result of implementing skin irritation study and repeated administration study in approximately 40 healthy volunteers, it was confirmed that no problems in terms of safety were found, thereby meeting the objective of these studies. From here on, based on the results of the studies, AnGes MG will prepare to implement phase II of the clinical trials.

Development in Japan of NFκB decoy oligo used in the treatment of atopic dermatitis is being carried out in alliance with Alfresa Pharma Corporation.